Skip to main content
. Author manuscript; available in PMC: 2019 Jul 31.
Published in final edited form as: Circulation. 2018 Jul 31;138(5):513–526. doi: 10.1161/CIRCULATIONAHA.117.031635

Figure 1. Bone Morphogenetic Protein 9 Expression is Increased in Heart Failure.

Figure 1

A) Representative immunoblots and B) quantitation of bone morphogenetic protein 9 (BMP9) and β-actin LV protein expression in patients with advanced heart failure referred for left ventricular assist device implantation (HF; n=8) compared to non-heart failure controls (non-HF; n=8). C) Plasma BMP9 levels measured by ELISA in patients with heart failure (HF; n=45) compared to non-heart failure controls (non-HF; n=10). D) LV BMP9 mRNA expression after two and eight weeks of transverse aortic constriction (TAC). n=3 independent experiments. E–F) Representative immunoblots and quantitation of LV BMP9, LV GAPDH and plasma BMP9 protein after two (n=4) and eight weeks (n=5) of TAC compared to Sham operated controls (n=4). Data are expressed as fold change vs. control. p<0.05: *, vs. Sham; †, vs. 2 wk TAC.